{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056294","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.650094+00:00","generated_at":"2026-06-02T06:26:27.725602+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PMV Pharma Q1 loss narrows to $15.3M; Phase 2 PYNNACLE trial initiated","bullets":["Net loss $15.3M vs $19.1M YoY; cash $213.1M, expected runway to end of 2026.","First patient dosed in registrational Phase 2 PYNNACLE trial for rezatapopt (TP53 Y220C/KRAS wild-type).","Phase 1 ovarian cancer data: 7/15 confirmed partial responses, median duration 7 months.","R&D expenses $13.2M (down from $15.1M); G&A $5.0M (down from $6.4M).","Net cash used in operations $16.2M vs $15.0M in Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056294","json":"https://secwatch.observer/filing/0000950170-24-056294.json","markdown":"https://secwatch.observer/filing/0000950170-24-056294.md","text":"https://secwatch.observer/filing/0000950170-24-056294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000095017024056294/0000950170-24-056294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000095017024056294/pmvp-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:26:27.725602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88d653676fed6b9622225315f4cd3375482c53ac","claim":"PMV Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $15.3 million.","evidence_excerpt":"PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699382/000095017024056294/0000950170-24-056294-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the quarter ended March 31, 2024, was $15.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}